Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D

A high percentage of patients with chronic kidney disease have hypovitaminosis D, which is a driver of secondary hyperparathyroidism and an important factor in chronic kidney disease-mineral and bone disorder. Vitamin D deficiency (serum total 25-OH vitamin D levels < 30 ng/mL) occurs early in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozzolino, Mario, Minghetti, Paola, Navarra, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995284/
https://www.ncbi.nlm.nih.gov/pubmed/34626363
http://dx.doi.org/10.1007/s40620-021-01152-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995284/
https://www.ncbi.nlm.nih.gov/pubmed/34626363
http://dx.doi.org/10.1007/s40620-021-01152-5

Ejemplares similares